Amgen’s KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer, Cancer, Chemotherapy, Clinical Trials, Immunotherapies, KRAS G12C Mutations, Overall Response Rate (ORR), R&D, RAS Genes, Solid Tumors Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Read more October 6, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/10/Amgens-KRAS-Inhibitor-Sotorasib-Effective-in-Non-Small-Cell-Lung-Cancer-BioSpace-10-6-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-10-06 12:01:322020-10-06 12:40:07Amgen's KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer